NeuroBotanics operates under conditional B2C market authorization issued by the Los Santos State Health Commission. All products have undergone preliminary toxicological review and have cleared the standards required for controlled consumer distribution.
SOMA-9® has successfully completed preliminary toxicological screening conducted under the auspices of the Los Santos State Health Commission's Advanced Implementation Research Protocol (AIRP). Testing assessed acute toxicity, subchronic exposure markers, and psychoactive compound concentration stability across three independent batch samples.
No adverse systemic toxicity was identified at standard consumer dosage ranges. The thermo-active tryptamine compound expressed by the SOMA-9® strain was classified as a Schedule IV controlled analogue under the Los Santos Controlled Substances Regulatory Framework — permitting controlled consumer distribution under the Advanced Implementation Protocol.
By resolution of the Los Santos State Health Commission dated Q4 2025, NeuroBotanics LLC has been granted conditional authorization for direct-to-consumer (B2C) distribution of SOMA-9® within the geographic jurisdiction of Los Santos, San Andreas State.
Authorization is conditional upon: (a) distribution exclusively through licensed NeuroBotanics-operated retail channels, including the HQ Smoking Lounge and approved membership programs; (b) maintenance of batch testing records accessible to commission inspectors upon request; (c) prohibition on distribution to individuals under the age of 21; (d) consumer disclosure of psychoactive compound classification at point of sale.
Wholesale resale to third-party retailers is subject to a separate licensing application currently under review.
The designation SOMA-9® is a registered trademark of NeuroBotanics LLC, registered under the San Andreas Intellectual Property Registry, Registration No. SA-IPR-2025-0441. All rights reserved.
The SOMA-9® cultivar — including the proprietary genetic modification protocol applied to the founding seed stock — constitutes a trade secret under applicable San Andreas commercial law. Unauthorized reproduction, propagation, or genetic analysis of SOMA-9® plant material is prohibited and subject to civil and criminal liability.
The N-ZYME MATRIX formulation methodology is the exclusive intellectual property of NeuroBotanics LLC. Client-specific formulas are proprietary to each client; the underlying methodology and compound sourcing protocols are proprietary to NeuroBotanics.
All components of the N-ZYME MATRIX formulation — including Lion's Mane, Chaga, and Reishi adaptogenic extracts, peptide compounds, amino acid derivatives, and vitamin and mineral supplementation — are classified as dietary supplements under the Los Santos Food, Drug and Supplement Safety Act.
Cultivation of adaptogenic fungi is conducted within NeuroBotanics' in-house clean room facilities under Good Manufacturing Practice (GMP) protocols. Batch testing for contamination, mycotoxin presence, and active compound concentration is conducted prior to formulation.
SOMA-9® contains psychoactive compounds. Consumption will alter perception and cognitive state. Do not operate motor vehicles or heavy machinery under the influence of SOMA-9®. Consult a licensed physician before use if you are pregnant, nursing, have a diagnosed psychiatric condition, or are prescribed controlled medications.
N-ZYME MATRIX formulations are individualized health products. They are not intended to diagnose, treat, cure, or prevent any disease. Biomarker analysis conducted at NeuroBotanics HQ does not constitute a medical diagnosis. NeuroBotanics consultants are not licensed physicians.
All NeuroBotanics products are restricted to individuals aged 21 and over. Valid identification is required at point of collection.
Reach us directly via Discord. We respond to compliance and legal inquiries within 48 hours.
// Contact via Discord